TY - JOUR IS - 1 Y1 - 2026/01// N2 - Human metapneumovirus (hMPV) is one of the potential pandemic pathogens, and it is a concern for elderly subjects and immunocompromised patients. There is no vaccine or specific antiviral available for hMPV. We conducted an in-silico study to predict initial antiviral candidates against human metapneumovirus. Our methodology included protein modeling, stability assessment, molecular docking, molecular simulation, analysis of non-covalent interactions, bioavailability, carcinogenicity, and pharmacokinetic profiling. We pinpointed four plant-derived bio-compounds as antiviral candidates. Among the compounds, apigenin showed the highest binding affinity, with values of ? 8.0 kcal/mol for the hMPV-F protein and ??7.6 kcal/mol for the hMPV-N protein. Molecular dynamic simulations and further analyses confirmed that the protein-ligand docked complexes exhibited acceptable stability compared to two standard antiviral drugs. Additionally, these four compounds yielded satisfactory outcomes in bioavailability, drug-likeness, and ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) and STopTox analyses. This study highlights the potential of apigenin and xanthoangelol E as an initial antiviral candidate, underscoring the necessity for wet-lab evaluation, preclinical and clinical trials against human metapneumovirus infection. AV - public TI - In silico prediction, molecular docking and simulation of natural flavonoid apigenin and xanthoangelol E against human metapneumovirus UR - http://doi.org/10.1007/S40203-025-00539-7 SN - 2193-9616 ID - uninimx26965 KW - Human metapneumovirus ˇ Antivirals ˇ Drug discovery ˇ In-silico ˇ Molecular docking ˇ Dynamic simulation ˇ Pharmacokinetics ˇ ADME-Tox VL - 14 JF - In Silico Pharmacology A1 - Rahaman, Hasan Huzayfa A1 - Khan, Afsana A1 - Sharif, Nadim A1 - Ahmed, Wasifuddin A1 - Sharif, Nazmul A1 - Majumder, Rista A1 - Aparicio Obregón, Silvia A1 - Calderón Iglesias, Rubén A1 - De la Torre Díez, Isabel A1 - Dey, Shuvra Kanti ER -